STUDboardsPlay · Research · Self · Fit · Money · Learn · Study · Plan · Token STUDtokenOptional

STUDresearch · Peptide

Dual/triple agonist research class (non-reta)

Also known as

multi-agonist peptides · glucagon/GIP/GLP-1 class talk · dual GLP-1/GIP agonists · dual GLP-1/glucagon agonists · triple agonist class (excluding retatrutide) · incretin multi-agonists · next-gen metabolic agonists · dual/triple G agonists · GIP/GLP-1 dual class · GCG/GLP-1 dual class · oxyntomodulin-analog duals · multi-receptor incretin peptides

Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.

Open in the directory ↗
Peptide Niche talk Systemic Subcutaneous (daily / weekly) Metabolic / GLP-1 class

Systemic multi-receptor metabolic peptides acting on appetite, glycemia, energy expenditure and hepatic fat; not local injury injects.

What people say This is a class page for multi-receptor metabolic agents, not one interchangeable drug. It includes GIP/GLP-1 agents such as tirzepatide and GLP-1/glucagon agents such as survodutide, mazdutide, pemvidutide, efinopegdutide and cotadutide. Doses people talk about
Tirzepatide weekly bands2.5 mg starting amount; 5, 10 and 15 mg maintenance targets

The label uses 2.5 mg for four weeks and increases of 2.5 mg no more frequently than every four weeks; these values apply to tirzepatide.

Survodutide weekly trial bands0.6, 2.4, 3.6 and 4.8 mg in Phase 2; 3.6 and 6.0 mg Phase 3 targets

The Phase 2 design included about 20 weeks of escalation followed by maintenance; the later targets belong to a different program.

Mazdutide weekly trial and discussion bands3, 4.5 and 6 mg; 4, 6 and 9 mg in other programs; exploratory work up to about 16 mg

Community charts echo 1.5–3 mg starting discussion followed by 3, 6 and optional 9 mg holds, but unverified vials are not equivalent to trial product.

Pemvidutide weekly trial bands1.2, 1.8 and 2.4 mg in obesity; 1.2 and 1.8 mg in MASH

The program and endpoint determine which bands were studied; 2.4 mg was not the public IMPACT pair recorded in the profile.

Efinopegdutide research schedulesExample weekly steps of 2.4, 5 and 10 mg; every-other-week designs also exist

These are study designs for efinopegdutide, not a default class schedule.

Cotadutide historical daily bands50, 100, 200 and 300 microgram step-ups; broader work explored up to about 600 micrograms

Cotadutide’s short exposure supported daily rather than weekly research dosing.

The rows retain the profile’s named-agent amounts and their trial settings without turning a class comparison into a progression or home protocol.

Half-life & effect duration

Half-life in the body
  • TirzepatideAbout 5–6 days
  • Survodutide · secondary estimateAbout 6 days
  • Pemvidutide · secondary estimateAbout 144 hours — roughly 6 days
  • CotadutideAbout 8.5–10.8 hours
Felt duration people report
  • Survodutide appetite reportsAbout 2–3 days or all week; some report no appetite suppression
  • Other experiencesBrief or severe nausea, reflux, sleepiness or energy changes, depending on compound and account
Timing context & sources
How it may feel Named-agent reports conflict. In an inspected survodutide trial thread, people described two-to-three days of appetite reduction, severe nausea and vomiting after a 2.4 mg increase, reflux without appetite suppression, or about six hours of nausea with week-long appetite effects. These cannot be generalized to the class.
Cycles people discuss Clinical programs use chronic weekly treatment over many months, including 46–76-week windows. A short bodybuilding-style cycle is not the evidence model, and informal breaks do not create one class-wide restart rule. Timing There is no class-wide half-life. Tirzepatide is about five to six days, while a human cotadutide study reported roughly 8.5–10.8 hours; felt appetite or GI timing must also stay attached to a named agent and amount. Stacks Trials generally study one named multi-agonist with lifestyle counseling. Community discussions more often describe switching agents than co-injecting two full multi-agonists, for which the profile records essentially no trial support. Watch for GI class effects: Nausea, vomiting, diarrhea, constipation, abdominal pain, early satiety, and reduced appetite — worst during titration and at higher weekly targets.
Related
TirzepatideSurvodutideMazdutidePemvidutideRetatrutide

Tap a line to jump into the full notes. Research only — may be wrong.

Timing context & sources

Half-life in the body

The class has no single bodily half-life.

Tirzepatide has an elimination half-life of about five to six days, whereas a single-dose human cotadutide study reported terminal half-life values of about 8.5–10.8 hours across renal-function groups.

Different receptor balances, molecular extensions, formulations and study designs prevent a class-wide range from being a useful pharmacokinetic value.

Felt duration people report

There is no defensible class-wide felt-duration window.

Inspected survodutide participants described appetite effects lasting two to three days or all week, short nausea, severe post-escalation nausea and vomiting, or reflux without appetite suppression. Mazdutide discussions added different early nausea, sleepiness and energy reports.

The posts involve different named agents, blinded allocation or unverified products, different amounts, prior incretin exposure and co-agents. They cannot define one class experience.

  • Reddit r/survodutide — Week of 4/29 thread (opens in a new tab)Multiple participant posts describe agent- and amount-specific appetite and GI timelines, including 1.2 mg effects for two to three days, severe nausea and vomiting after a 2.4 mg increase, reflux without appetite suppression, and about six hours of nausea with appetite suppression through the week.Unverified identities and assignments, mixed prior exposure and no standardized measurement; comments should not be combined into one participant or class effect.
  • Reddit r/Biohacking — Mazdutide (opens in a new tab)A commenter reports first-week nausea and sleepiness followed by adaptation over a month; the thread also contains a separate survodutide-plus-tirzepatide report with different effects.Unverified products and self-selected reports; compound identity, amounts and co-agents vary, so the thread cannot establish a mazdutide or class felt-duration value.

Other context in this card

What people say 23

  • Appetite / food noise (class community): Earlier satiety, smaller meals, quieter food thinking when a tolerated maintenance dose is held — shared incretin experience, not unique to one dual. forum
  • Cross-trial ranking caveats: Different baselines (BMI, ethnicity, T2D mix), lifestyle co-interventions, estimands (treatment-policy vs efficacy), and completer bias make “X is better than Y by N%” forum charts fragile. forum
  • Class step-up pattern (cross-trial): Mono-GLP-1 (e.g. semaglutide ~15% class figures at full obesity dose/time) → dual GIP/GLP-1 (tirzepatide up to ~20.9% SURMOUNT-1 style) → glucagon-containing duals/triples (mid-teens to ~20%+ depending on molecule/window) is the common comparison ladder — not a single RCT ranking all agents. trial
  • Tirzepatide glycemic (T2D programs): Large HbA1c reductions with multi-mg weekly pens; dual GIP/GLP-1 is the approved “beyond mono-GLP-1” diabetes/obesity standard in many markets. trial
  • Survodutide Phase 2 obesity (46 weeks, planned treatment): Mean −6.2% (0.6 mg), −12.5% (2.4 mg), −13.2% (3.6 mg), −14.9% (4.8 mg) vs −2.8% placebo. trial
  • Survodutide Phase 2 completer/on-treatment headline: Up to ~18.7% mean weight loss at 4.8 mg when actual dose received is emphasized — the “nearly 19%” press figure. trial
  • Survodutide MASH Phase 2 (biopsy, 48 weeks): MASH improvement without fibrosis worsening reported ~47% (2.4 mg), ~62% (4.8 mg), ~43% (6.0 mg) vs ~14% placebo — strong liver narrative vs pure weight agents. trial
  • Survodutide liver fat (SYNCHRONIZE-MASLD / imaging): High rates of ≥30% relative MRI-PDFF reduction (e.g. ~84% class figures on drug vs ~24% placebo in Phase 3 MASLD coverage); visceral and liver fat drops framed as organ-selective add-ons. trial
  • Mazdutide GLORY-1 Phase 3 (China, 4 / 6 mg, 48 weeks): Treatment-policy means roughly −11% (4 mg) / −14% (6 mg) vs near-zero placebo in public trial tables — solid dual GCG/GLP-1 obesity signal. trial
  • Mazdutide GLORY-2 Phase 3 (9 mg, 60 weeks): Mean ~18.55% vs ~3.02% placebo overall; non-T2D subgroup ~20.08% mean with ~48.7% hitting ≥20% loss — “>20% with short titration” company messaging. trial
  • Mazdutide Phase 2 (≤6 mg, 24 weeks): Mean ~−6.7% / −10.4% / −11.3% at 3 / 4.5 / 6 mg vs ~+1% placebo — early dual ladder that still anchors community 3→6 talk. trial
  • Mazdutide glycemic (DREAMS T2D program): Double-digit relative weight plus ~1.5–2% class HbA1c drops in China Phase 3; head-to-head vs dulaglutide / semaglutide used in “beats mono” comparisons (population-specific). trial
  • Mazdutide liver fat (Phase 2 obesity, high-dose arm): Relative LFC drops on the order of ~70%+ at 9 mg in reported MRI windows — glucagon-arm liver story shared with survodutide/pemvidutide. trial
  • Pemvidutide MOMENTUM Phase 2 obesity (48 weeks): Mean ~10.3% (1.2 mg), ~11.2% (1.8 mg), ~15.6% (2.4 mg) vs ~2.2% placebo — high-dose ~15–16% at year-ish mark without multi-month reta-style ladder. trial
  • Pemvidutide MASLD/MASH: Large relative MRI-PDFF reductions (often 50–70%+ class figures by dose/window) and IMPACT Phase 2b MASH-resolution signals at 1.2 / 1.8 mg — liver + fat dual pitch. trial
  • Pemvidutide lipids / BP: Strong triglyceride drops and BP reductions without large heart-rate spikes in some obesity/NAFLD readouts — sometimes contrasted with HR-raising glucagon duals. trial
  • Cotadutide (historical dual): Once-daily short-acting GLP-1/glucagon co-agonist showed metabolic/hepatic signals in Phase 2; AstraZeneca ended the daily program (~2023) to prioritize weekly follow-ons — still appears in class history and gray-market name lists. trial
  • Cardiometabolic bundle: Waist, BP, lipids, and liver enzymes commonly move with large weight loss across dual programs; size of effect tracks dose, duration, and baseline metabolic disease. trial
  • Body composition honesty: Fat mass drives most scale change; lean mass still falls with large absolute loss unless protein + resistance training are prioritized — class, not molecule-unique. trial
  • Tirzepatide (GIP/GLP-1 dual) weight (SURMOUNT-1, 72 weeks): Mean losses about −15.0% (5 mg), −19.5% (10 mg), −20.9% (15 mg) vs ~−3.1% placebo in the flagship obesity RCT framing — the dual-GIP benchmark everyone else is measured against. trial
  • Survodutide SYNCHRONIZE-1 Phase 3 (76 weeks, public coverage): Treatment-regimen means roughly mid-teens (~12–13% class figures at 3.6 / 6.0 mg vs higher placebo in some summaries); efficacy-estimand / full-adherence framing pushes higher (~15–17% class headlines at 6.0 mg). Always check estimand before comparing. trial
  • Pemvidutide body composition (MOMENTUM MRI substudy): ~78% of lost weight as fat / ~22% as lean in company framing — “lean preservation” marketing that communities cite vs historical ~25–40% lean-share fears on other incretins (cross-trial, not head-to-head). trial
  • Efinopegdutide (MK-6024) liver fat: Phase 2a NAFLD work reported ~70%+ relative LFC reduction at 10 mg weekly-style escalation vs lower figures on semaglutide comparator arms in the same design — liver-first dual framing. trial

Doses people talk about 21

  • Survodutide community reality: Few dense personal mg charts; when research vials appear, people usually copy trial ladders (low start → multi-month climb toward 3.6–6 mg class targets) rather than invent independent microdose cultures. forum
  • Mazdutide community charts: Research-peptide sites and forums commonly echo 1.5–3 mg starts, then 3 → 6 → optional 9 mg weekly holds; unit conversion talk assumes labeled vial strength (often unreliable). China branded Xinermei pen culture is separate from Western gray vials. forum
  • Do not average mg across class: Potency, receptor bias (GIP vs GCG balance), and formulation differ — 2.4 mg pemvidutide is not “half of” 4.8 mg survodutide in any meaningful equipotent sense. forum
  • Gray-market vial risk: Labels rarely prove identity, receptor profile, purity, endotoxin status, or fill accuracy; underdosed, overdosed, or wrong-peptide products are a documented community concern for multi-agonist SKUs. forum
  • Split-dose debate (borrowed from tirz/reta culture): Some multi-agonist users split weekly total into two SC injections ~3–4 days apart aiming for flatter peaks / less nausea; total weekly mg kept similar — unvalidated vs once-weekly trial designs for most duals. forum
  • Missed dose heuristics (class forums): If far from next weekly day, take when remembered; if close, skip — practices vary; only tirzepatide has mature branded missed-dose labeling. forum
  • Framing: Ranges below are trial arms and community discussion only — not medical advice, not approved labeling for investigational agents, not a gray-market endorsement. Milligrams are molecule-specific. forum
  • Route (class default): Once-weekly subcutaneous injection is the dominant modern clinical design for long-acting multi-agonists. trial
  • Mazdutide exploratory high dose: Phase 1-style work up to ~16 mg weekly in small Western overweight/obesity cohorts — early, not a marketed regimen. trial
  • Pemvidutide obesity / MOMENTUM arms: 1.2 mg, 1.8 mg, 2.4 mg once weekly × 48 weeks. trial
  • Pemvidutide titration culture: 1.2 and 1.8 mg often full-start; 2.4 mg used a short ~4-week ramp in MOMENTUM — no multi-month 8–20 week ladder like tirz/reta public schedules. trial
  • Pemvidutide MASH / IMPACT doses: 1.2 mg and 1.8 mg weekly (2.4 mg not the IMPACT pair in public summaries). trial
  • Cotadutide (historical daily): Once-daily SC microgram bands in trials (e.g. 50→100→200→300 μg step-ups; broader programs explored up to ~600 μg class ranges) — short half-life drove daily, not weekly, use before program wind-down. trial
  • Tirzepatide (GIP/GLP-1) maintenance bands: 5 mg, 10 mg, 15 mg once weekly after escalation; obesity SURMOUNT-style 72-week programs use these targets. trial
  • Tirzepatide titration (label / trial culture): Start 2.5 mg weekly × 4 weeks, then +2.5 mg every ≥4 weeks through 5 → 7.5 → 10 → 12.5 → 15 mg as tolerated; max adult 15 mg weekly. trial
  • Survodutide Phase 2 dose-finding arms: 0.6, 2.4, 3.6, 4.8 mg once weekly for 46 weeks (≈20-week escalation + 26-week maintenance). trial
  • Survodutide Phase 3 SYNCHRONIZE targets: 3.6 mg and 6.0 mg once weekly after multi-step up-titration (often ~4-week steps in public design descriptions); flexible delay / temporary reduction allowed for GI in protocols. trial
  • Mazdutide Phase 2 / DREAMS-style bands: 3 mg, 4.5 mg, 6 mg weekly with short ladders (examples: 1.5→3 mg; 1.5→3→4.5 mg; 2→4→6 mg over multi-week steps). trial
  • Mazdutide GLORY / high-dose obesity: 4 mg and 6 mg (GLORY-1); 9 mg target (GLORY-2) with company emphasis on a short 2-step titration to 9 mg in that program. trial
  • Efinopegdutide (MK-6024) example ladder (Phase 2a NAFLD): Escalation toward ~10 mg weekly (public schemes include steps like 2.4 → 5 → 10 mg over successive weeks); Q2W alternate-dosing studies also exist in later designs. trial
  • Titration philosophy (class): Multi-week to multi-month escalation is standard for long-acting weekly agents; jumping straight to top trial dose is not Phase 2/3 practice and drives GI dropouts. trial

How it may feel 8

  • Constipation shift: Early diarrhea can flip to constipation at maintenance — class pattern that surprises mid-run. forum
  • Days 1–7: First appetite drop and early fullness common after first weekly shot; nausea, loose stools, or fatigue may appear — or almost nothing until dose escalates. trial
  • Weeks 1–4 (onboarding): GI events cluster at start and at each titration step. Visible scale change is often modest until a therapeutic weekly dose is held. trial
  • Weeks 4–12: Weight and appetite usually separate from baseline if dose is climbing or held in the effective band; many discontinuations in dual programs happen during escalation. trial
  • Months 3–6: Common window where dual/triple arms show clear double-digit mean separation from placebo in Phase 2 designs; community logs debate “hold here” vs push higher. trial
  • Months 6–12+: Phase 3 obesity windows often ~48–76 weeks; chronic weekly use is the clinical model, not a short cut cycle. Some high-dose curves still decline late (e.g. pemvidutide 2.4 mg near-linear talk; mazdutide GLORY-2 60-week continuity). trial
  • Each dose increase: GI often spikes 1–2 weeks then settles at a stable held dose; vomiting, intake collapse, or severe constipation are hold/step-down flags. trial
  • Heart-rate arc (glucagon-containing agents): Mild resting HR rise is a monitored trial theme for several GCG duals/triples; pemvidutide obesity coverage sometimes emphasizes less HR lift — molecule-specific, not class-identical. trial

Cycles people discuss 8

  • Breaks / time off: Discussed for GI reset, travel, supply gaps, cost, or personal preference — with strong class concern for appetite rebound and regain. forum
  • Restart rule of thumb: Re-titrate from a lower weekly step after a multi-week break; jumping back to prior max often re-flares hard GI. forum
  • Not a short recomp stack: Systemic multi-agonists are not GLOW/Wolverine-style injury courses or 6-week cut injectables by design — some PED forums still use them that way (confounded). anecdote
  • Clinical model: Chronic once-weekly therapy for many months (often 48–76+ weeks in Phase 3) — not 4–8 week bodybuilding “blasts.” trial
  • Titration = early phase: Reaching a held maintenance dose often takes weeks to months depending on molecule (short for some pemvidutide arms; long for tirz 2.5→15 and survodutide multi-step climbs). trial
  • Maintenance framing: Trials and community treat multi-agonists as ongoing metabolic therapy; “cycle off every X weeks” is not the evidence-based obesity model. forum
  • After goal weight: Lower maintenance dose vs full stop is the main fork; full stop associates with regain risk across incretins. trial
  • Molecule-specific run lengths people cite: Tirz multi-year real-world use; survodutide 46–76 week trial windows; mazdutide 48–60 week Phase 3; pemvidutide 48 week obesity / 24–48 week liver — continuous weekly exposure. trial

Timing 12

  • Injection habit: Same weekday preferred for habit and comparability of side-effect timing. forum
  • Washout: Multi-week residual effect expected after last weekly dose for long-acting agents; “cleared in 48 hours” claims do not match multi-day half-lives. forum
  • Long-acting design: Fatty-acid / albumin-binding extensions (and proprietary domains like pemvidutide EuPort) enable once-weekly SC exposure for modern duals. trial
  • Survodutide PK: Plasma half-life ~6 days with high albumin binding — weekly steady-state logic. trial
  • Pemvidutide PK: Terminal half-life often cited ≈144 hours / ~6 days; EuPort framed as slowing absorption and supporting weekly full-start lower doses. trial
  • Tirzepatide PK: Multi-day half-life supporting weekly pens (class long-acting incretin PK); branded labels define timing/missed-dose rules. trial
  • Mazdutide PK: Once-weekly fatty-acid–extended OXM-analog design; multi-day exposure underpins weekly China pen / research-vial culture. trial
  • Cotadutide contrast: Short human half-life (~8–10 hours class figures) forced once-daily dosing — why weekly duals displaced daily cotadutide-style programs. trial
  • Why weekly: Extended exposure and compliance; multi-daily pens are the exception (historical or special formulations), not the class default. trial
  • Steady-state lag: Full effect lags first injection because of titration and multi-week approach to steady state — early weeks are not “max drug yet.” trial
  • Feel vs measure: Appetite and food-noise changes are felt first; glucagon-arm energy/liver effects are more often inferred from imaging (MRI-PDFF, visceral fat) and labs than as a daily “burn” sensation. trial
  • Downstream pathways (class): GLP-1 → CNS satiety + gastric emptying; GIP → islet/glucose and weight synergy; glucagon → hepatic fuel mobilization / energy-expenditure narratives — balance differs by molecule (tirz has no GCG arm; survodutide/mazdutide/pemvidutide do). trial

More on what it is 9

  • Triple (non-reta) note: True GIP/GLP-1/glucagon triples beyond retatrutide are sparse in public late-stage obesity talk; most “triple” forum chatter still points at reta. This page covers multi-agonist class logic without collapsing into reta dosing. forum
  • Why discussed: Pipeline and gray-market talk frames multi-agonists as the step after mono-GLP-1 (semaglutide class) for larger mean % weight loss, stronger liver-fat endpoints, and different side-effect balances. forum
  • Not one drug: Molecules are not interchangeable by milligram. Survodutide 4.8 mg ≠ mazdutide 6 mg ≠ pemvidutide 2.4 mg ≠ tirzepatide 15 mg. forum
  • Access split: Tirzepatide has branded / compounded / gray channels in many markets; most glucagon duals remain investigational or region-approved (e.g. mazdutide China) with thinner personal-log culture. forum
  • Research lens: Always map claims to a named agent, receptor pair, trial phase, dose, and duration — “dual agonist” alone is not a protocol. forum
  • What it is: A research class of multi-receptor peptides that combine GLP-1 activity with GIP and/or glucagon (dual or triple). This class page excludes retatrutide (has its own profile) and groups the other dual/triple agents people compare. trial
  • Two main dual families: (1) GIP/GLP-1 duals — flagship approved agent tirzepatide; (2) GLP-1/glucagon (GCG) duals — survodutide, mazdutide, pemvidutide, efinopegdutide, cotadutide (program history). trial
  • Mechanism (plain): GLP-1 → satiety + slower gastric emptying + glucose-dependent insulin; GIP → glucose handling and weight synergy with GLP-1 (tirz model); glucagon → energy expenditure / hepatic fat oxidation narratives on top of intake cut. trial
  • Evidence honesty: Named Phase 2–3 programs exist with hard numbers per molecule; class-level “upgrade path” lore is comparison talk across different trials, populations, and time windows — not head-to-head proof that every dual beats every mono. trial

Stacks 9

  • Lifestyle stack (near-universal community advice): High protein, resistance training, sleep, and step count credited for better composition and fewer “skinny-fat” outcomes under hard appetite suppression. forum
  • Switch ladder, don’t co-inject: Forums debate progression semaglutide → tirzepatide → glucagon dual / reta more than stacking two multi-agonists at once. forum
  • No dual multi-agonist stack: Combining two full GLP-1-pathway multi-agonists (e.g. tirz + survodutide, or dual + reta) is treated as redundant receptor load with compounded GI, gallbladder, and hypo risk when glucose drugs are present — essentially no trial support. forum
  • Support tactics (class): Smaller meals, slower eating, anti-nausea habits, fiber/electrolytes for bowel swings, adequate fluids — adjunct habits, not proven molecule-specific stacks. forum
  • Sparse adjuncts: Occasional lipid agents, sleep aids, or recovery peptides appear in n=1 logs with weak attribution to the multi-agonist’s effect. anecdote
  • PED-forum pairings: Some bodybuilding contexts pair multi-agonists with AAS/TRT for recomp — confounded, not clinical practice, and not a dosing standard. anecdote
  • No GLOW/Wolverine-style fixed ratio blend: Multi-agonists are single engineered peptides (or fixed co-formulations in amylin programs), not homemade multi-vial injury blends. forum
  • Monotherapy default: Obesity and MASLD trials study multi-agonists alone + lifestyle counseling — not BPC-157 / TB-500 / GHK-Cu injury stacks. trial
  • Amylin adjacency (related, not this class core): Cagrilintide and CagriSema (cagri + sema) appear in the same “next-gen metabolic” conversation as duals/triples but are amylin ± GLP-1, not GIP/GCG duals — separate profile territory. trial

Storage notes 2

  • No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
  • Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum

Watch for 15

  • Lean mass / sarcopenia concern: Hard appetite cut without protein + lifting can produce undesirable composition even when scale weight drops fast. forum
  • Fatigue / dehydration: Secondary to low intake, GI losses, or rapid weight drop — common community complaints during aggressive titration. forum
  • Source / identity risk: Gray-market “dual/triple” vials may be wrong peptide, wrong dose, degraded, or contaminated; analytical verification is hard for end users. forum
  • Not one upgrade path: GIP duals (tirz) vs GCG duals (survo/mazdu/pemvi) change the benefit/side balance — liver-fat upside and HR/GI profiles are not identical. forum
  • Cross-trial hype risk: Comparing peak completer % from one dual to intention-to-treat means from another inflates “winner” charts. forum
  • GI class effects: Nausea, vomiting, diarrhea, constipation, abdominal pain, early satiety, and reduced appetite — worst during titration and at higher weekly targets. trial
  • Discontinuation: GI drives many trial dropouts across dual programs; slow escalation, temporary holds, and step-downs are the usual clinical responses. trial
  • Gallbladder / biliary: Rapid weight-loss contexts include cholelithiasis and biliary event talk — shared GLP-1-class risk pattern, not dual-exclusive. trial
  • Heart rate (glucagon arm): Some GCG-containing duals/triples raise resting HR monitoring points in trials; magnitude and clinical importance are molecule- and dose-dependent. trial
  • Hypoglycemia: Low intrinsic risk as monotherapy in non-insulin users; risk rises if stacked with insulin or sulfonylureas in T2D settings. trial
  • Pancreatitis / thyroid class cautions: Community risk lists often import boxed-warning-style GLP-1 class language (pancreatitis discussion; MTC/MEN2-style cautions) — finished consumer labels exist for approved agents (tirz) and are incomplete for investigational duals. trial
  • Injection-site reactions: Local redness, itch, or nodules appear in AE tables at variable rates by formulation. trial
  • Investigational honesty: Outside approved indications and products (primarily tirzepatide in many markets; mazdutide in China for specified uses), most duals lack consumer labels, long-term post-marketing safety, and verified pharmacy supply. trial
  • Not risk-free: Meaningful weight and liver signals sit next to real GI burden, open long-term questions for newer duals, and zero purity guarantee on research chemicals. trial
  • Pregnancy / fertility: Not established as safe; metabolic drugs are generally avoided in pregnancy research framing. trial

Updated: 2026-08-12

Evidence mix More trial/lab tags than forum tags Full: every bullet (trial + community). Use Scan for a faster bro-science read.
↑ Back to top

All STUDresearch topics →